Notably, in the total XVII study, T-ALL patients who presented ABL-class fusions with partner genes such as NUP214, ETV6, SLC9A3R1 or MBNL1 were also included in the dasatinib sub-arm jointly with B-ALL ABL-class fusion positive patients. The gene discussed is MBNL1; the disease is acute lymphoblastic leukemia.